Last reviewed · How we verify
CQ and PQ starting on Day 42
CQ and PQ starting on Day 42 is a Antimalarial agents Small molecule drug developed by Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. It is currently in Phase 3 development for Malaria (Plasmodium vivax and Plasmodium ovale with relapse prevention), Uncomplicated malaria treatment and relapse prophylaxis. Also known as: Standard treatment with no potential synergy.
CQ (chloroquine) and PQ (primaquine) are antimalarial agents that inhibit parasite DNA replication and metabolism, with PQ also targeting hypnozoites to prevent relapse.
CQ (chloroquine) and PQ (primaquine) are antimalarial agents that inhibit parasite DNA replication and metabolism, with PQ also targeting hypnozoites to prevent relapse. Used for Malaria (Plasmodium vivax and Plasmodium ovale with relapse prevention), Uncomplicated malaria treatment and relapse prophylaxis.
At a glance
| Generic name | CQ and PQ starting on Day 42 |
|---|---|
| Also known as | Standard treatment with no potential synergy |
| Sponsor | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado |
| Drug class | Antimalarial agents |
| Target | Parasite heme polymerase (CQ); hypnozoite mitochondrial electron transport (PQ) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Chloroquine accumulates in parasite food vacuoles and inhibits heme polymerization, disrupting DNA replication and causing parasite death. Primaquine is a prodrug metabolized to active metabolites that generate reactive oxygen species, particularly effective against the dormant liver stage (hypnozoites) of P. vivax and P. ovale, preventing relapse infections. The combination targets both blood and tissue stages of malaria parasites.
Approved indications
- Malaria (Plasmodium vivax and Plasmodium ovale with relapse prevention)
- Uncomplicated malaria treatment and relapse prophylaxis
Common side effects
- Gastrointestinal disturbance (nausea, vomiting, abdominal pain)
- Headache
- Hemolytic anemia (PQ, especially in G6PD deficiency)
- Pruritus
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CQ and PQ starting on Day 42 CI brief — competitive landscape report
- CQ and PQ starting on Day 42 updates RSS · CI watch RSS
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado portfolio CI
Frequently asked questions about CQ and PQ starting on Day 42
What is CQ and PQ starting on Day 42?
How does CQ and PQ starting on Day 42 work?
What is CQ and PQ starting on Day 42 used for?
Who makes CQ and PQ starting on Day 42?
Is CQ and PQ starting on Day 42 also known as anything else?
What drug class is CQ and PQ starting on Day 42 in?
What development phase is CQ and PQ starting on Day 42 in?
What are the side effects of CQ and PQ starting on Day 42?
What does CQ and PQ starting on Day 42 target?
Related
- Drug class: All Antimalarial agents drugs
- Target: All drugs targeting Parasite heme polymerase (CQ); hypnozoite mitochondrial electron transport (PQ)
- Manufacturer: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Malaria (Plasmodium vivax and Plasmodium ovale with relapse prevention)
- Indication: Drugs for Uncomplicated malaria treatment and relapse prophylaxis
- Also known as: Standard treatment with no potential synergy
- Compare: CQ and PQ starting on Day 42 vs similar drugs
- Pricing: CQ and PQ starting on Day 42 cost, discount & access